Atezolizumab in non-small cell lung cancer: the era of precision immuno-oncology.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Systematic profiling of immune signatures identifies prognostic predictors in lung adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020
   Article
2. CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.Cancer cell international · 2020
   Review
3. Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them.Translational lung cancer research · 2017
   Article
4. Atezolizumab in advanced non-small cell lung cancer.Journal of thoracic disease · 2017
   Article

Corrections and comments

• Comment on
  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.